DGS Capital Management LLC Takes Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

DGS Capital Management LLC bought a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,571 shares of the company’s stock, valued at approximately $156,000.

A number of other institutional investors and hedge funds have also modified their holdings of CLBT. Swiss National Bank boosted its stake in Cellebrite DI by 7.6% during the first quarter. Swiss National Bank now owns 89,000 shares of the company’s stock worth $570,000 after buying an additional 6,300 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Cellebrite DI by 159.3% during the first quarter. JPMorgan Chase & Co. now owns 49,499 shares of the company’s stock worth $317,000 after acquiring an additional 30,410 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of Cellebrite DI by 3,021.1% during the first quarter. Blair William & Co. IL now owns 523,978 shares of the company’s stock valued at $3,353,000 after acquiring an additional 507,190 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Cellebrite DI in the 1st quarter valued at $127,000. Finally, State Street Corp grew its holdings in shares of Cellebrite DI by 20.3% in the 1st quarter. State Street Corp now owns 155,440 shares of the company’s stock worth $995,000 after purchasing an additional 26,240 shares during the last quarter. 21.80% of the stock is currently owned by institutional investors.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock opened at $7.28 on Thursday. The firm has a 50 day simple moving average of $7.55 and a 200 day simple moving average of $6.47. Cellebrite DI Ltd. has a fifty-two week low of $3.80 and a fifty-two week high of $8.29. The firm has a market cap of $1.42 billion, a P/E ratio of -34.67, a P/E/G ratio of 0.93 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Tuesday, August 8th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.03 by $0.02. Cellebrite DI had a positive return on equity of 60.26% and a negative net margin of 13.89%. The company had revenue of $76.70 million during the quarter, compared to analysts’ expectations of $72.52 million. During the same period last year, the firm earned $0.00 EPS. The business’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, sell-side analysts expect that Cellebrite DI Ltd. will post 0.19 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Craig Hallum began coverage on shares of Cellebrite DI in a research report on Wednesday, July 19th. They issued a “buy” rating and a $11.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Cellebrite DI in a report on Wednesday, August 30th. TheStreet raised Cellebrite DI from a “d+” rating to a “c” rating in a report on Thursday, July 13th. JPMorgan Chase & Co. boosted their price objective on Cellebrite DI from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. Finally, Bank of America increased their target price on Cellebrite DI from $6.15 to $6.75 in a report on Friday, June 16th.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.